Additionally, it has well known that PCa develops to neuroendocrine prostate cancer (NEPC), which is the most deadly subtype of PCa when PCa develops abiraterone resistance, and expressed typical NEPC markers including NCAM1 (CD56) and SYP [32, 33]. Here, NCAM1 is linked to posterior cortical atrophy.